137 related articles for article (PubMed ID: 10229097)
1. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
Ressing ME; de Jong JH; Brandt RM; Drijfhout JW; Benckhuijsen WE; Schreuder GM; Offringa R; Kast WM; Melief CJ
Eur J Immunol; 1999 Apr; 29(4):1292-303. PubMed ID: 10229097
[TBL] [Abstract][Full Text] [Related]
2. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
[TBL] [Abstract][Full Text] [Related]
3. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
[TBL] [Abstract][Full Text] [Related]
6. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
7. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions.
Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB
Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843
[TBL] [Abstract][Full Text] [Related]
8. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice.
Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC
J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625
[TBL] [Abstract][Full Text] [Related]
9. Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.
Peng S; Xing D; Ferrall L; Tsai YC; Roden RBS; Hung CF; Wu TC
mBio; 2022 Feb; 13(1):e0325221. PubMed ID: 35089069
[TBL] [Abstract][Full Text] [Related]
10. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
van der Burg SH; Ressing ME; Kwappenberg KM; de Jong A; Straathof K; de Jong J; Geluk A; van Meijgaarden KE; Franken KL; Ottenhoff TH; Fleuren GJ; Kenter G; Melief CJ; Offringa R
Int J Cancer; 2001 Mar; 91(5):612-8. PubMed ID: 11267969
[TBL] [Abstract][Full Text] [Related]
11. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
12. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
13. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope.
Alexander M; Salgaller ML; Celis E; Sette A; Barnes WA; Rosenberg SA; Steller MA
Am J Obstet Gynecol; 1996 Dec; 175(6):1586-93. PubMed ID: 8987945
[TBL] [Abstract][Full Text] [Related]
14. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented.
Bauer M; Wagner H; Lipford GB
Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786
[TBL] [Abstract][Full Text] [Related]
15. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7-derived peptide.
Jochmus I; Osen W; Altmann A; Buck G; Hofmann B; Schneider A; Gissmann L; Rammensee HG
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1689-95. PubMed ID: 9225046
[TBL] [Abstract][Full Text] [Related]
16. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
Oerke S; Höhn H; Zehbe I; Pilch H; Schicketanz KH; Hitzler WE; Neukirch C; Freitag K; Maeurer MJ
Int J Cancer; 2005 May; 114(5):766-78. PubMed ID: 15609316
[TBL] [Abstract][Full Text] [Related]
17. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope.
Ressing ME; van Driel WJ; Celis E; Sette A; Brandt MP; Hartman M; Anholts JD; Schreuder GM; ter Harmsel WB; Fleuren GJ; Trimbos BJ; Kast WM; Melief CJ
Cancer Res; 1996 Feb; 56(3):582-8. PubMed ID: 8564975
[TBL] [Abstract][Full Text] [Related]
18. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.
Youde SJ; McCarthy CM; Thomas KJ; Smith KL; Man S
Int J Cancer; 2005 Apr; 114(4):606-12. PubMed ID: 15609329
[TBL] [Abstract][Full Text] [Related]
19. A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11-20) cytotoxic T lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Lemonnier FA; Meijer CJ; Hooijberg E
Vaccine; 2005 Jul; 23(31):4005-10. PubMed ID: 15963358
[TBL] [Abstract][Full Text] [Related]
20. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
